Compositions for generating immune tolerance by targeting erythrocytes

Patent metadata

Field	Value
Publication number	US-9878048-B2
Application number	US-201615232714-A
Country	US
Kind code	B2
Filing date	Aug 9, 2016
Priority date	Aug 10, 2010
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

First claim

What is claimed is:

1. A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising:
an antigen that results in an unwanted immune response upon administration of the antigen to a subject and recognition of the antigen by an immune cell;
wherein said antigen comprises Factor VIII;

an erythrocyte-binding moiety,
wherein said erythrocyte-binding moiety comprises an antibody fragment
wherein the antigen is fused with the erythrocyte-binding moiety;
wherein said erythrocyte-binding moiety does not specifically bind to other blood components other than glycophorin-A;

wherein said composition is suitable for intravenous delivery to the subject;
wherein said erythrocyte-binding moiety has the ability to non-covalently bind an erythrocyte in situ in blood; and
wherein said binding results in the antigen being presented to the immune system and results in antigen-specific tolerance.

2. The composition of claim 1 , wherein the antibody fragment is derived from a 10F7 clone.

3. The composition of claim 1 , wherein the erythrocyte-binding moiety is fused to the antigen at the N- or C-terminus of the antigen.

4. The composition of claim 3 , wherein the erythrocyte-binding moiety is capable of binding said glycophorin A with an affinity generating a dissociation constant of between about 10 μM and 0.1 nM as determined by equilibrium binding measurements between the erythrocyte-binding moiety and erythrocytes.

5. The composition of claim 1 , wherein the erythrocyte-binding moiety comprises an antibody fragment derived from a hybridoma that produces an antibody against an erythrocyte.

6. The composition of claim 5 , wherein the erythrocyte-binding moiety is an affinity matured antibody fragment.

7. The composition of claim 5 , wherein the erythrocyte-binding moiety comprises an antibody fragment that is affinity matured and derived from a 10F7 clone.

8. A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising:
an antigen selected from the group consisting of Factor VIII and fragments thereof, the antigen being chemically conjugated with at least one erythrocyte-binding moiety, an immune system of the subject being able to respond to or previously having responded to the antigen with an unwanted immune response,
said erythrocyte-binding moiety having the ability to non-covalently bind an erythrocyte surface in situ in blood and present said antigen to the immune system of the subject in a tolerogenic manner,
wherein said erythrocyte-binding moiety has the ability to bind to an erythrocyte surface molecule selected from the group consisting of Band 3 (CD233), glycophorin-A, glycophorin B (CD235b), glycophorin C (CD235c), and glycophorin D (CD235d),
wherein said erythrocyte-binding moiety comprises a protein or peptide ligand,
wherein said erythrocyte-binding moiety does not specifically bind to other blood components, and
wherein the erythrocyte-binding moiety has a dissociation constant of between about 10 μM and 0.1 nM as determined by equilibrium binding measurements between the erythrocyte-binding moiety and erythrocytes.

9. The composition of claim 8 , wherein the erythrocyte-binding moiety comprises a peptide ligand, wherein multiple copies of the erythrocyte-binding moiety are conjugated to the antigen at a plurality of sites on the antigen.

10. The composition of claim 8 , wherein the peptide ligand is selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

11. The composition of claim 8 , wherein the protein comprises an antibody fragment, wherein the antibody fragment is derived from a 10F7 clone, and wherein the antibody fragment is capable of binding human glycophorin A.

12. The composition of claim 11 , wherein the antibody fragment has undergone affinity maturation.

13. A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising:
an antigen fused or chemically conjugated with an erythrocyte-binding moiety;
said antigen comprising a therapeutic protein or peptide;
said antigen being recognizable by an immune system of a subject, the immune system of the subject being able to respond to or previously having responded to the antigen with an unwanted immune response,
said erythrocyte-binding moiety having the ability to non-covalently, specifically bind an erythrocyte surface in situ in blood and present said antigen to the immune system of the subject,
wherein said erythrocyte-binding moiety has the ability to bind glycophorin A with an affinity generating a dissociation constant of between about 10 μM and 0.1 nM as determined by equilibrium binding measurements between the erythrocyte-binding moiety and erythrocytes, and
wherein said erythrocyte-binding moiety comprises a peptide, an antibody, or an antibody fragment.

14. The composition of claim 13 , wherein the therapeutic protein or peptide is Factor VIII, wherein the antigen is fused with the erythrocyte-binding moiety, and wherein the erythrocyte-binding moiety is derived from a 10F7 clone.

15. The composition of claim 13 , wherein the erythrocyte-binding moiety comprises a peptide ligand and wherein multiple copies of the erythrocyte-binding moiety are conjugated to the antigen at a plurality of sites on the antigen.

16. The composition of claim 13 , wherein the erythrocyte-binding moiety is fused to the antigen at the N- or C-terminus of the antigen.

17. The composition of claim 13 , wherein the erythrocyte-binding moiety comprises an antibody, an antibody fragment, or a single chain variable fragment (scFv).

18. The composition of claim 17 , wherein the antibody, antibody fragment, or scFv has undergone affinity maturation.

19. The composition of claim 17 , wherein the antibody, antibody fragment, or scFv is derived from a hybridoma that produces an antibody against an erythrocyte.

20. The composition of claim 17 , wherein the antibody, antibody fragment, or scFv is derived from a 10F7 clone.

21. The composition of claim 13 , wherein the erythrocyte-binding moiety comprises a peptide ligand selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

Assignees

• École Polytechnique Fédérale De Lausanne (Epfl)
• Ecole Polytechnique Fed De Lausanne (Epfl)

Inventors

• Hubbell Jeffrey A
• Kontos Stephan
• Dane Karen Y

Classifications

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C12Y305/01001

  Asparaginase (3.5.1.1) · CPC title

• C07K14/62

  Insulins · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title

• A61K39/001

  Preparations to induce tolerance to non-self, e.g. prior to transplantation · CPC title